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1. Introduction
Photodynamic therapy is a treatment that exploits the interac-
tion of light with a photosensitive drug in the presence of mo-
lecular oxygen.[1–3] Such an interaction produces cytotoxic reac-
tive oxygen species that may induce the death of the targeted
tumor cells.[4, 5] The advantage of photodynamic therapy lies in
its potential to achieve high selectivity towards the diseased
tissues through the following therapeutic mechanism: the
drug is administered to the patient and, after a specific inter-
val, in which the drug accumulates in the tumor tissues, the in-
terested region is irradiated with a source of light with appro-
priate wavelength.[2, 3, 5] Chlorin derivatives are second-genera-
tion photosensitizers widely employed in approved clinical
treatments and also in clinical trials.[1, 6, 7] These compounds are
porphyrin-based species,[8] in which one of the double bonds
has been reduced to enhance the light absorption at lower en-
ergies,[9] in the so-called therapeutic window.[4] The best per-
formance of second-generation photosensitizers over first-gen-
eration photosensitizers is well illustrated when comparing Te-
moporfin (mTHPC) to PhotofrinS, with the former being 100
times more photoactive than the latter.[10,11]
However, porphyrin derivatives present several disadvantag-
es, especially at the time of administration into patients. In
polar media, like water or blood, porphyrins tend to form ag-
gregates,[11,12] which are less photoactive[13] and considerably
diminish the efficacy of the treatment.[14] This is the case for
mTHPC (see Figure 1a), currently employed in photodynamic
therapy to treat certain types of cancer and precancerous con-
ditions.[11,15,16] This drug is nowadays administrated as FoscanS
(biolitec pharma Ltd.) within an ethanol/propylene glycol mix-
ture and it has shown aggregation and precipitation phenom-
ena at the moment of injection, when the photosensitizer
enters the blood stream. Liposomes have been identified as
valuable nanocarriers of hydrophobic drugs, favoring the accu-
mulation of the photosensitizer in the tumor tissues and solv-
ing the solubility issue in the administration phase of the treat-
ment.[17] As shown in Figure 1b, liposomes consist of an assem-
bly with a hydrophilic inner cavity formed by the phosphate
groups of the lipids, which contains water inside, a hydropho-
bic inner part of the double layer formed by the alkyl chains,
and an outer polar spherical surface also formed by the phos-
phate groups.
The efficacy of liposomal formulations of chlorin derivatives
has been demonstrated for mTHPC, in which the drug has
been embedded in the non-polar region of the liposome, as it
is the case of the FoslipS formulation. First, these formulations
solve the solubility problem, providing an easier administration
of the drug to the patient, as the final product can be dis-
persed in water and administrated orally, intravenously, or
through skin permeation.[18,19] Second, FoslipS and other lipo-
some formulations show a higher efficiency with respect to
FoscanS, presenting a larger selectivity for tumor tissues with
respect to healthy ones and provoking faster dissociation of
Liposomal formulations facilitate the administration of hydro-
phobic drugs, avoiding precipitation and aggregation phenom-
ena when injected in polar solvents. The integration of the
photosensitizer into the liposome may alter the fluidity of the
system and, thus, modify the delivery process of the drug.
Such a change has been observed for the liposomal formula-
tion of Temoporfin, which is one of the most potent chlorin
photosensitizers employed in photodynamic therapy. Here, all-
atom molecular dynamics simulations have been performed to
identify the nature of the intermolecular interactions that
might be responsible of the different lipids freedom of motion
when the drug is introduced in the bilayer. It is found that Te-
moporfin participates as a hydrogen donor in strong hydro-
gen-bonding interactions with the polar groups of the phos-
pholipids. The theoretical analysis suggests that the rigidity of
drug/liposome complexes can be modulated by considering
the different hydrogen-bond ability of the photosensitizer and
the carrier material.
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the tumor cells, which results in more effective growth inhibi-
tion.[17,20–23] More importantly, liposomal formulations of Temo-
porfin do not manifest any dark toxicity.[21,24] Finally, the liposo-
mal formulation ensures the presence of the drug in its mono-
meric form, which is the most photoactive species.[25,26]
The factors that most influence the success of a liposomal
formulation are the loading capacity of the carrier and the re-
lease of the drug to the targeted cells, that is, the actual deliv-
ery process. Both factors are regulated by the interactions be-
tween the vehicle material and the drug. To provide an opti-
mal formulation, such interactions should be of medium
strength so that the drug is safely hosted in the carrier, but its
release is not hindered. Intermolecular interactions, therefore,
play a very important role in the transport and delivery of the
drug,[27] and the elucidation of the nature of such interactions
is relevant to design nanocarriers with optimal properties.
Different molecular compositions for possible mTHPC liposo-
mal formulations have been investigated by differential scan-
ning calorimetry and electron spin resonance spectroscopy.[28]
The latter has shown that the photosensitizer is located in the
hydrophobic part of the double layer and that its presence
hinders the motion of the phospholipids, giving more rigid
vesicles.[28] Thus, the drug–lipid interactions lower the molecu-
lar motion of the phospholipids. However, the nature of these
interactions, responsible for the high loading capacity of the
carrier and its different fluidity is unknown.
Coarse-grained methods are typically used to investigate the
structural behaviour of loaded and pure liposomes.[29,30] How-
ever, these methods are not able to provide atomistic details,
such as interatomic interactions responsible for the final struc-
tural properties of the system. Therefore, in this work, we have
performed all-atom classical molecular dynamics simulations to
unveil the nature of the lipid–drug interactions that might be
relevant in the liposomal formulation FoslipS as a model for
chlorin-based photosensitizers. We show that hydrogen bond-
ing between the photosensitizer and the phosphate heads of
the lipids is the main interaction responsible for the large load-
ing capacity of the carrier and the different mobility shown by
the phospholipids in calorimetric experiments and electron
spin resonance measurements.[28,31]
2. Results and Discussion
2.1. Convergence to a Steady State
The first step in any molecular dynamics simulation of a large
system is to obtain an equilibrated structure. However, this is
very hard to achieve in liposomes of small size, which are
metastable systems that converge very slowly to a steady
state.[32] Liposomes with diameters smaller than 20 nm have a
very high propensity to fuse with other liposomes, forming
larger vesicles such that the stress imposed by the high curva-
ture of small spherical shapes, which constrains the lipids to
be very tightly packed, is released.[33] Therefore, the relatively
small-sized liposome modelled in this work (diameter of
12.6 nm; see Figure 2a) undergoes very strong curvature ef-
fects, which influence the packing of the phospholipids and
make equilibration very difficult.
Commonly, coarse-grained methods are employed to study
lipid vesicles, allowing larger sizes (20–34 nm of diameter) and
longer simulation times,[32,34] at the price of losing atomistic in-
sight. Even in such cases, the definition of a true steady state
is extremely difficult and requires simulation times that can
reach hundreds of microseconds.[34] Achieving a true equilibrat-
ed structure, in fact, would require the simulation of phenom-
ena like the flip-flop of phospholipids between the inner and
outer shell of the double layer as well as water exchange be-
tween the inner cavity of the liposome and the surrounding
solvent.[32]
In this work, we have monitored two parameters to analyze
the structural quasi-equilibration of the system: the area per
Figure 1. a) Structure of the simulated liposome; the mTHPC molecules are
represented in red, the phosphate groups of the DPPC and DPPG molecules
are represented in blue and cyan, respectively, whereas the alkyl chains are
pictured in grey. The structure has been clipped to show also the inner layer
of the double layer. The structural formula of the two phospholipids 1,2-di-
palmitoyl-sn-glycero-3-phosphocholine (DPPC) and 1,2-dipalmitoyl-sn-glyc-
ero-3-phosphorylglycerol sodium salt (DPPG) and the Temoporfin (mTHPC)
photosensitizer are shown. b) Schematic representation of the structure of a
liposome and of a phospholipid, highlighting the polar head and the hydro-
phobic tails.
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lipid AL of the two layers of the membrane and the hydration
number of the polar heads of the phospholipids. These two
properties converge very slowly to a steady value in flat lipid
membranes and are, therefore, employed as criteria to define
the equilibrium of the system.[35] The area per lipid AL has been
calculated considering the two spherical surfaces formed by
the phosphorus atoms of the polar heads of the lipid chains,
as shown in Figure 2a. The radius of such spheres was calculat-
ed at intervals of 0.5 ns along the heating simulation in the
canonical ensemble (constant number of atoms, volume and
temperature [NVT]) and at intervals of 10 ns along the simula-
tion in the isothermal-isobaric ensemble (constant number of
atoms, pressure and temperature [NPT]). The average radius (r)
obtained for the inner and outer leaflets was employed to cal-
culate the area of the two surfaces defined by the phosphate
groups of the lipids (Figure 2a). Then, the area per lipid is
given by the area of the surface divided by the number of
lipid molecules of the leaflet (NL) [Eq. (1)]:
AL ¼ ð4phrðin=outÞi2Þ=NLðin=outÞ ð1Þ
As seen in Figure 2b, AL presents strong oscillations along
the NVT heating step, especially for the outer shell of lipid mol-
ecules. Instead, in the simulation at constant pressure (NPT), AL
reaches a constant value almost immediately. The area per
lipid of the inner leaflet oscillates around 0.4 nm2 with a small
deviation in the last 20 ns of the simulation, where it slightly
increases up to 0.49 nm2. This shows that a full equilibrated
structure is hard to achieve for relatively small liposomes, as
explained above. The AL value for the outer shell molecule is
1.02 nm2 and remains stable throughout the whole NPT simula-
tion. The observed inner-leaflet structural fluctuations is a con-
sequence of the curvature of the double layer, which influence
the stability of the membrane inner leaflet to a larger extent.[32]
The experimental AL for flat phospholipids double layers is
found in a range of 0.55–0.72 nm2.[35] However, such values are
only valid for very large vesicles where the surface locally ap-
proximate a flat bilayer. The small size of our theoretical model
induces a high curvature that constrains the inner shell lipids
to be very tightly packed, whereas the ones in the outer layer
are more loosely arranged. As there is no free lunch, such geo-
metrical alterations introduce an error in the simulated AL. Pre-
vious molecular dynamics simulations,[29,30] employing a
coarse-grained model to describe a liposome, reported AL
values for the inner and outer shells of 0.5 and 0.8 nm2, respec-
tively, that is, in better agreement with the experimental esti-
mation, but still affected by the spherical shape of the bilayer.
As intermolecular interactions are relevant for the structural
properties of the bilayer,[36] we have selected the hydration
number as the second parameter to monitor the equilibration
process, which directly correlates with AL. The hydration
number represents the total number of water molecules per
polar lipid head present in the first solvation shell of the lipo-
some. This has been calculated by integrating the first peak of
the radial distribution function of the water molecules and the
negatively charged phosphate oxygen atom of the DPPC
lipids.[35] As seen in Figure 2c, the hydration number shows im-
portant oscillations during the heating simulation, but it con-
verges to a value of 1.52 water molecules after 20 ns in the
NPT simulation. We conclude, therefore, that the drug/lipo-
some assembly is relatively well equilibrated after 20 ns of dy-
namics in the NPT ensemble, attending to the time evolution
of the area per lipid and the hydration number, which were
recommended convergence criteria.[35] Accordingly, the follow-
ing analyses are performed using frames from the dynamics
between 20 and 100 ns.
Figure 2. a) Representation of all the phosphate atoms located in the inner
shell (blue) and outer shell (red) used to calculate the surface areas in the
model liposome. The outer radius of the model liposome is reported in
nanometers. b) Time evolution of the area per lipid (AL) for the inner and
outer leaflets of the bilayer along the simulations. c) Time evolution of the
hydration number of the lipid polar heads forming the bilayer.
ChemistryOpen 2018, 7, 475 – 483 www.chemistryopen.org T 2018 The Authors. Published by Wiley-VCH Verlag GmbH&Co. KGaA, Weinheim477
2.2. Diffusion Coefficients
As shown by electron spin resonance spectroscopy experi-
ments,[28] the integration of mTHPC into the liposome induces
a lowering in the molecular freedom of motion of the lipids.
This change in the mobility is a consequence of the different
chemical environment experienced by the lipid chains when
they are in the presence of the drug versus when they are lo-
cated in the pure liposome. The appearance of new intermo-
lecular interactions might induce an increase or decrease of
the lipid motion, depending on the strength of the drug–lipid
interactions. The lowering of the motion, experimentally ob-
served,[28] indicates that the interactions in the loaded lipo-
some are stronger than in the pure one.
To theoretically investigate the effect of the drug on the mo-
bility of the lipids, we have calculated the root-mean-square
displacement (RMSD) of the lipids along the 100 ns of the sim-
ulation in the NPT ensemble by considering different regions
of the liposome, defined by the separation between the lipids
and a drug molecule (see Figure 3a). We expect that the lipids
in the immediate surroundings of the drug present less fluidity
because of possible strong drug–lipid intermolecular interac-
tions. First, the RMSD of the mTHPC molecules (without lipids)
has been computed. Then, we have extended the analysis to
the surrounding lipid molecules, gradually increasing the dis-
tance from the drug molecules between 2 and 10 a, as sketch-
ed in Figure 3a. The RMSD of the lipids located in the different
regions, plotted in Figure 3b, clearly evidences that the lipid
molecules in the immediate surroundings of the drug mole-
cules show less freedom of motion. In other words, the farther
the residues are from the drug, the larger is their freedom of
motion and, therefore, their displacement along the simula-
tion. This behavior indicates that the lipid molecules interact
stronger with the drug than with other lipid molecules, and
that their motion is reduced with respect to the situation
where they are surrounded by only other lipid molecules. A
more quantitative analysis can be performed by calculating
the diffusion coefficient D from the mean-square displacement
(MSD), along the simulation time t, using the so-called Einstein
relation [Eq. (2)]:[37,38]
MSD ¼ 6Dt ð2Þ
The MSD of the last 80 ns of the simulation is linearly fitted
and the slope provides the diffusion constant D of the lipid
residues located at different distances from the drug. Figure 3c
shows that the variation of the diffusion coefficient with the
separation r from the drug residues can be interpolated by the
increasing exponential function D(r)=AeB(r)+D0, where A, B,
and D0 are fitting parameters with values of @0.008 a2ps@1,
@0.289 a@1, and 0.01 a2ps@1. This indicates that the diffusion
coefficient of the lipid chains increases with the separation be-
tween the lipids and the drug, and it reaches the value of
0.01 a2ps@1 at larger distances, where drug–lipid interactions
are less significant or absent and are replaced by lipid–lipid in-
teractions. In addition, the fast increase of D with the distance
r from the drug residues (D reaches half of its maximum value
already at a drug–lipid separation of only 2.5 a) confirms that
the interactions controlling the system are of short-range
character.
After confirming that the liposome presents larger rigidity
due to the intermolecular interactions between the drug and
the phospholipids, the next step was to identify the nature of
such interactions. To this aim, first, we investigated which frag-
ments of the lipid chains, namely heads or tails, play a more
significant role in the interactions with the drug molecules.
Thus, the RMSD in the NPT ensemble is computed for the
polar heads and the nonpolar tails of the phospholipids. In ad-
dition, this analysis (Figure 4) is performed by considering two
Figure 3. a) Schematic representation of the drug Temoporfin and the sur-
rounding residues used in the RMSD analysis. The molecules represented
with bolder lines are found in a sphere of 2 a radius centered at the drug.
Thinner lines represent instead residues inside a sphere of 10 a radius.
b) RMSD of the residues contained in the different size spheres surrounding
the drug residues during the NPT simulation. c) Diffusion coefficient reported
against the separation from the drug molecules. The color scheme is the
same as in (b).
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different regions of the carrier material : 1) lipid chains located
in the proximity of a drug molecule within a sphere of 2 a,
and 2) less influenced lipid chains located in a region of 10 a
from a drug molecule (see Figure 3a). In the case of the resi-
dues in the immediate surroundings of the drug molecules
(cutoff of 2 a, Figure 4a), the RMSD of the drug and the polar
heads almost overlap and oscillates around a RMSD of 13 a.
The nonpolar tails, instead, show a larger mobility with an
average RMSD value of 20 a throughout the simulation. The
smaller mobility of the polar heads in comparison with the
nonpolar tails clearly points to an existing interaction between
the polar heads and mTHPC. Considering now the RMSD of
the residues at farther distances from the drug (cutoff of 10 a,
Figure 4b), the coupling between the polar heads and drug
molecules is lost, and the tail and head residues show approxi-
mately the same freedom of motion. Clearly, the drug–head in-
teractions, which are evident at short distances, vanish at
larger separations, where the motion of the lipids is less per-
turbed by the presence of the drug.
The large number of hydrogen donor and acceptor atoms
present in both the drug and polar heads of the phospholipids
(Figure 1a) and the short-range character of the drug/head in-
teractions, as indicated by the rapid change of the diffusion
coefficient of the lipids with the distance from the drug (Fig-
ure 3c), suggest that hydrogen bonding is responsible for the
rigidity in the proximity of the Temoporfin molecules.
2.3. Hydrogen-Bond Analysis
The presence of a network of hydrogen bonds between
mTHPC molecules and the polar heads of the lipids would ex-
plain the rigidity of the phospholipids in the direct proximity
of the drug molecules. Hydrogen bonds are, in fact, interac-
tions that are particularly relevant in a hydrophobic environ-
ment, where water molecules cannot easily interfere. Hydrogen
bonds are also somewhat directional interactions and can form
rather ordered structures. Finally, the presence of hydrogen
bonds between the photosensitizer and the carrier material
would assure a good loading capacity of the vesicle.[27]
The polar heads of the DPPC lipids are hydrogen acceptors,
whereas the polar heads of the DPPG lipids and the drug mol-
ecules can act as both hydrogen donors and acceptors in the
formation of hydrogen bonds. Therefore, we can classify the
hydrogen bonds as drug–drug, head–drug, and head–head hy-
drogen bond pairs, see Scheme 1.
According to the coupling of the polar head and the drug
motion found in the analysis of the RMSD reported in Fig-
ure 4a, the drug–head hydrogen bonds are strong enough to
lower the freedom of motion of the phospholipids.
The strength of a hydrogen bond is intimately related with
the geometrical parameters of the atoms involved in the inter-
action, specifically, with the hydrogen donor–hydrogen accep-
tor distance rD-A and with the angle qD-H-A formed by hydrogen
donor, hydrogen atom, and hydrogen acceptor shown in
Scheme 1d. Table 1 shows the total number of hydrogen
bonds found along the full simulation, the number of hydro-
gen bonds that last for more than half of the simulation time,
the total number of fragment pairs that can potentially form
Figure 4. Comparison of the RMSD of the polar heads and the hydrophobic
tails of the lipid molecules in a region of a) 2 a and b) 10 a radius around
the drug residues. The RMSD of the drug is also reported as reference.
Scheme 1. Schematic representation of the three categories considered for
the hydrogen-bond analysis : drug–drug pair forming a hydrogen bond (a),
drug–head pair involved in a hydrogen bond (b), and two phospholipids
connected through a hydrogen bond between the polar head residues (c).
The tails of the phospholipids are pictured in gray, whereas, for the residues
involved in the bonds, the color scheme is red for oxygen atoms, blue for ni-
trogen, tan for phosphate, cyan for carbons, and white for hydrogens. d) A
zoom on the atoms involved in the hydrogen bond (encircled in yellow in
the previous panels), with the geometrical parameters shown.
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hydrogen bonds, and the average values of the geometrical
parameters for the different categories of hydrogen bonds. We
consider a hydrogen bond formed when rD-A is smaller than
3 a and qD-H-A is larger than 1358. As reported in Table 1, the
number of long-lived head–drug hydrogen bonds (27) is larger
than the number of long-lived head–head hydrogen bonds
(12), despite the number of head–drug pairs (113050) being
smaller than the number of head–head pairs (116886). Al-
though the number of hydrogen bonds depends on the
number of species considered in the box, the present numbers
clearly indicate that the lipid chains are more prone to partici-
pate in hydrogen bonding with the drug than with other lipid
chains. In addition, the head–drug hydrogen bonds are not
only more abundant but also stronger, as indicated by the
smallest rD-A value (2.67 a) and the largest qD-H-A value (1628).
A more quantitative picture is obtained by considering the
distribution of the hydrogen-bond lifetimes and geometrical
parameters obtained by the analysis of all hydrogen bonds
formed along the simulation. Figure 5a shows the number of
drug–drug, head–drug, and head–head hydrogen bonds,
grouped according to their lifetimes as a percentage of the
total simulation time. Head–head hydrogen bonding domi-
nates at short lifetimes (less than 10% of simulation time),
whereas they are surpassed by the drug–head hydrogen
bonds at longer lifetimes, especially at lifetimes over 70% of
the simulation time. The drug–head distribution in Figure 5a
presents a minimum at a life time of 50%; such a feature is
just a result of the way the distribution was built and has no
physical meaning.
To compare the strength of the interactions between the
three different pairs of residues, the probability distribution of
rD-A and qD-H-A is depicted in Figures 5b and 5c, respectively.
The rD-A distribution peaks at a shorter distance for the drug–
head interaction (2.67 a) than those for the head–head (2.69 a)
and the drug–drug (2.83 a), whereas the qD-H-A distribution
peaks occur at larger angles for the drug–head interaction
(1628 and 1648) than for head–head (1618) and the drug–drug
(1608) ones. Therefore, both the hydrogen-bond lifetimes and
the probability distribution of the geometrical parameters indi-
cate that the hydrogen-bond strengths follow the order drug–
head > head–head > drug–drug. The stronger hydrogen
bonds found between Temoporfin and the polar heads explain
why the mobility of the phospholipids is smaller in close prox-
imity to the drug. In addition, the hydrogen-bond behavior
also explains the good loading capacity of the liposomes and
the loss of mobility of several liposomal formulations of
mTHPC.[28]
Finally, we discuss the reasons behind the stronger interac-
tions between the photosensitizer and the lipid heads than be-
tween different lipid heads. A closer inspection of the atoms
involved in hydrogen bonding reveals that, in the drug–head
interaction, mTHPC plays the role of hydrogen donor from its
phenol moieties virtually all the time, whereas, in the head–
head interaction, the hydrogen donor atoms are the O atoms
Table 1. Number of hydrogen bonds (HBs) identified along the dynamics,
HBs that last for more than half of the simulation time (long-lived HBs),
total number of interacting pairs, average value of the D–A distance rD-A
and average value of the D–H–A angle qD-H-A for the three hydrogen
bond categories. The geometrical parameters are shown in Scheme 1d.
HB pair [a] Total HBs Long-lived HBs Number of pairs rD-A [a] qD-H-A [8]
H–H 424 12 116886 2.70 160
H–D 249 27 113050 2.67 162
D–D 76 7 780 2.85 157
[a] H–H stands for a head–head pair, H–D for a head–drug pair, and D–D
for a drug–drug pair.
Figure 5. a) Number of drug–drug, drug–head, and head–head hydrogen
bond pairs grouped according to their persistency in percentage during the
simulation time. b) Probability distribution of donor-acceptor distances rD-A.
c) Probability distribution of donor-hydrogen-acceptor angles qD-H-A.
ChemistryOpen 2018, 7, 475 – 483 www.chemistryopen.org T 2018 The Authors. Published by Wiley-VCH Verlag GmbH&Co. KGaA, Weinheim480
of the ethylene glycol moiety of the DPPG lipids (see Fig-
ure 1a). Owing to the electron-withdrawing effect of the aro-
matic ring of the phenolic substituent, mTHPC is a better hy-
drogen donor than the glycol moiety of the DPPG. In general,
aromatic alcohols are better hydrogen donors than aliphatic
ones. This is the reason why phenol acts as a hydrogen donor
and methanol as a hydrogen acceptor in the phenol–methanol
dimer.[39] Based on our analysis, one can conclude that the ri-
gidity of the liposomal formulation of mTHPC, closely related
with the loading and release capacity of the liposome, can be
modulated considering the strength of the hydrogen bonds
that the phenol moieties of the drug could form with phos-
pholipids suitable for liposomal formulations.
This consideration can be extended to different photosensi-
tizers baring H-bonding groups in their substituents. In case of
phenol moieties, further functionalization of the photosensitiz-
er can be pursued. If the functionalization enhances the elec-
tron-withdrawing ability of the aromatic ring, the drug would
be a better hydrogen donor and the drug/liposome assembly
would be more stable. Contrarily, if the aromatic ring loses its
electron-withdrawing ability upon functionalization, the drug is
a less effective hydrogen donor and the drug/liposome assem-
bly would be less stable. However, it is important to note that
such a functionalization should not modify other properties of
the drug, for example, its hydrophobicity or the energy of the
electronically excited states and, thus, the photosensitization
efficiency and mechanism of the drug should not be altered.
3. Conclusions
In this work, we have performed all-atom molecular dynamics
simulations to unravel the reasons behind the smaller mem-
brane fluidity experimentally found for several liposome formu-
lations of the photosensitizer Temoporfin,[28] a prototypical
chlorin photosensitizer. The analysis of the motion of the dif-
ferent residues composing the liposome and the calculation of
diffusion coefficients of the lipid chains in the immediate sur-
roundings of the photosensitizer have shown that the interac-
tions that confer rigidity to the drug/liposome assembly are of
short-range character. These interactions are identified as rela-
tively strong hydrogen bonds between the photosensitizer
and the polar heads of the phospholipids. Owing to electron
withdrawing effects, the drug is a powerful hydrogen donor
and, thus, the rigidity of the liposome induced by the drug
into the phospholipids in its immediate surroundings derives
from the tenacity of such interactions. Our theoretical analyses
suggest that the stability of Temoporfin liposomal formulation
could be also ascribed to the strength of the hydrogen bond
formed by the drug and the carrier material. Such considera-
tions on the hydrogen-bonding capability of the drug and the
phospholipids can be extended to other chlorin photosensitiz-
ers and, thus, can be relevant to design new drug formula-
tions, as intermolecular interactions between the drug and the
nanocarrier affect the loading capacity of the carrier, the drug
release process, and the pharmacokinetic properties of the
drug.[40]
Computational Details
The liposome initial structure was built with the Packmol soft-
ware package,[41] with a composition of DPPC/DPPG phospholi-
pids with a ratio of 9:1 (w/w) and with a molar ratio of lipid/
mTHPC of 12:1. The inner leaflet of the liposome bilayer is
formed by 118 phospholipid molecules confining 472 mole-
cules of water in the inner cavity. The number of water mole-
cules placed in the inner cavity was calculated so that the den-
sity of the solvent in the inner cavity equals the one that sur-
rounds the liposome. The second leaflet of the vesicle is as-
sembled from 366 lipid molecules, resulting in a liposome with
a diameter of about 126 a. The liposome also contains 40 mol-
ecules of Temoporfin, placed in the hydrophobic region of the
double layer, based on previous electron spin resonance spec-
troscopy measurements.[28] The resulting drug/liposome com-
plex was solvated with 109387 water molecules confined in a
cubic box of 83 a side. Na+ counter ions were added to neu-
tralize the DPPG negative charges and NaCl was added to
reach a salt concentration of 0.15 M.
The energy of the system was first minimized in seven steps.
In the first step, only 200 residues of the liposome were mini-
mized, whereas the other residues were spatially constrained
by employing a harmonic force constant of 50 kcalmol@1a@2.
In each of the next five steps, 200 more residues were allowed
to move during minimization together with the ones already
optimized in the previous steps. In the final minimization step,
the whole liposome was minimized without any constrains.
Each minimization calculation consists of 10000 steps, where
the first 5000 were performed by employing the steepest de-
scent algorithm while the last 5000 were performed by em-
ploying the conjugated gradient algorithm. The system was
then slowly heated in the canonical ensemble (NVT ensemble)
from 0 to 300 K in four different simulations of 1 ns each. In
the first three heating simulations, the temperature was in-
creased by 100 K intervals from 0 to 300 K. During the three
heating steps, the motion of the residues forming the lipo-
some was constrained with decreasing harmonic force con-
stants of 10, 5 and 1 kcalmol@1a@2. The last heating simulation
was performed at a fixed temperature of 300 K and with no
constraints applied on the motion of the drug/liposome as-
sembly. Afterwards, the system was run in the isothermal-iso-
baric ensemble (NPT ensemble) to equilibrate the density of
the system and the structure of the liposome for 100 ns, and
the snapshots were printed every 20 ps for analysis. As dis-
cussed above, after 20 ns, the system reached a metastable
state and, therefore, the last 80 ns of the simulation were em-
ployed in the analyses.
For all of the simulations, periodic boundary conditions were
applied and a time step of 2 fs was employed. The SHAKE al-
gorithm[42] was used to freeze bonds involving H atoms. The
Langevin thermostat was used with a collision frequency
gamma of 1.0 ps@1 while the pressure was kept fixed at 1 atm
with the Berendsen barostat and isotropic position scaling. For
the non-bonded interactions calculation, a cutoff of 10.0 a was
employed together with the particle-mesh Ewald method to
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calculate the coulombic interactions.[43] The phospholipids
were described by the Lipid17[44] force field, available in the
AmberTools17.[45] The intramolecular and Lennard–Jones pa-
rameters of the drug were taken from the general Amber force
field.[46] The restrained electrostatic potential (RESP) charges
were computed by density functional theory, employing the
B3LYP[47] functional and the 6-31G* basis set[48] using the Gaus-
sian09[49] software package. We employed the TIP3P model[50]
for the water molecules and appropriate Amber parameters to
describe the NaCl ions.[51] All the simulations were performed
with the GPU-based module PMEMD implemented in
AMBER16.[45]
The visualization of the simulation trajectories and the RMSD
calculations were performed with the visual molecular dynam-
ics (VMD) program,[52] the hydrogen-bond analysis was per-
formed with the CPPTRJ software[53] by employing a cutoff of
3 a for the D–A distance and 1358 for the D–H–A angle. By
using the Einstein relation, Equation (2), the RMSD curves were
linearly fitted to calculate the diffusion coefficient of the drug
and lipid molecules.
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